The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000826347p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
15/06/2026
Date registered
Help: Date registered
9/07/2026
Date last updated
Help: Date last updated
9/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
9/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
UPfront tOtal eradiCation versus delAyed treatment of persistent lesions with stereotactic ablative radiotHerapy for men with metastatic (4-10) hOrmone seNsitive prosTate cancer mAnaged with best Systemic therapy: a randomised phase II trial (POCAHONTAS)
Scientific title
UPfront tOtal eradiCation versus delAyed treatment of persistent lesions with stereotactic ablative radiotHerapy for men with metastatic (4-10) hOrmone seNsitive prosTate cancer mAnaged with best Systemic therapy: a randomised phase II trial on 3-year castration-resistant prostate cancer (CRPC)-free survival (POCAHONTAS)
Additional trial identifiers [1] 317578 0
Nil known
Universal Trial Number (UTN)
Trial acronym
POCAHONTAS
Related trial records

Health condition
Health condition(s) studied:
Prostate cancer 342329 0
Condition category
Condition code
Cancer 338458 338458 0 0
Prostate

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure

Participants randomised to Arm A will receive upfront stereotactic ablative radiotherapy (SABR) to all PSMA-PET–avid metastatic lesions (up to 10 sites). SABR dose and fractionation will be individualised according to lesion characteristics, proximity to organs at risk, and patient factors. Permitted regimens range from 20 Gy in a single fraction to 35–50 Gy in 5 fractions, with different lesions permitted to receive different dose-fractionation schedules.
SABR will be delivered by specialist radiation oncology teams over a short treatment course of 1–5 fractions, typically administered on alternate days for multi-fraction regimens. All SABR treatment must commence within 4 weeks of randomisation and is expected to be completed within approximately 1–2 weeks from treatment initiation, depending on the fractionation schedule and number of lesions treated.
In addition to SABR, all participants will receive standard-of-care systemic therapy consisting of androgen deprivation therapy (ADT) combined with an androgen receptor pathway inhibitor (ARPI), with or without chemotherapy, at the discretion of the treating clinician. Intermittent ADT is not permitted. Systemic therapy is intended to continue long-term in accordance with standard clinical practice and study follow-up requirements. For the purposes of the study, systemic therapy must be administered for a minimum of 6 months following randomisation and may continue for the duration of the participant's involvement in the study, with no protocol-specified maximum duration.
Intervention code [1] 334376 0
Treatment: Other
Description of the comparator or control
Comparator Group: Arm B – Delayed SABR
Arm B (Delayed SABR) comprises upfront systemic therapy followed by delayed SABR to residual disease. Systemic therapy is clinician-selected and typically consists of androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor (ARPI), with or without chemotherapy, administered according to standard of care and individualised based on patient and disease characteristics. SABR is subsequently delivered to residual PSMA-PET–avid metastatic lesions identified at the 6-month PSMA-PET/CT scan, rather than all baseline lesions. The dose and fractionation of SABR are individualised, determined by lesion-specific factors such as size, anatomical location, proximity to organs at risk, and patient considerations. Permitted regimens include 20 Gy in 1 fraction, 24 Gy in 2 fractions, 24–30 Gy in 3 fractions, and 35–50 Gy in 5 fractions, with flexibility for different lesions within the same patient to receive different regimens if clinically required.

In terms of duration, systemic therapy is administered upfront and continues for at least the initial 6-month period prior to SABR, and thereafter according to standard clinical practice with no fixed protocol duration. SABR is delivered as a short course over 1 to 5 fractions (typically over several days to ~1–2 weeks depending on fractionation schedule). SABR must be initiated within 4 weeks of the 6-month PSMA-PET/CT scan. Treatment is delivered within a radiotherapy department by appropriately qualified specialists, specifically radiation oncologists, who oversee planning, dose prescription, and delivery in accordance with protocol and local practice standards.
Control group
Active

Outcomes
Primary outcome [1] 345750 0
Three-year castration-resistant prostate cancer (CRPC)-free survival, defined as the proportion of participants who are alive and have not developed CRPC at 3 years following randomisation.
Timepoint [1] 345750 0
These assessments are performed during scheduled follow-up visits (every 3 months for the first 2 years, then 6-monthly), until 3 years post randomisation.
Secondary outcome [1] 463162 0
Time to Castration-Resistant Prostate Cancer (CRPC)
Timepoint [1] 463162 0
Assessment for the primary outcome (CRPC-free survival) is conducted through regular scheduled follow-up visits from the time of randomisation until development of CRPC, death, or censoring at last follow-up. Follow-up visits occur every 3 months (±2 weeks) for the first 24 months, and then every 6 months (±4 weeks) thereafter. Participants are followed for outcome assessment for up to 36 months post-randomisation (aligned with the primary endpoint of 3-year CRPC-free survival), with continued longer-term survival follow-up thereafter.
Secondary outcome [2] 463163 0
Time to Change in Systemic Therapy
Timepoint [2] 463163 0
These assessments occur at regular follow-up visits every 3 months (±2 weeks) for the first 24 months, and every 6 months (±4 weeks) thereafter, with additional documentation at unscheduled visits if treatment changes occur earlier due to disease progression or toxicity. The endpoint is assessed longitudinally from randomisation until a change in systemic therapy occurs, or censoring at last follow-up
Secondary outcome [3] 463164 0
Cumulative Incidence of Adverse Events (AEs)
Timepoint [3] 463164 0
Cumulative incidence of adverse events (AEs) is assessed longitudinally over the entire study follow-up period, beginning from baseline (and specifically from the commencement of SABR for SABR-related AEs) and continuing until the end of each participant’s follow-up. AEs are captured at scheduled visits every 3 months for the first 24 months and every 6 months thereafter, as well as at any unscheduled visits, with all events cumulatively analysed across this full observation period (up to at least 3 years post-randomisation).
Secondary outcome [4] 463165 0
Prostate Cancer–Specific Survival
Timepoint [4] 463165 0
Evaluations occur at scheduled follow-up visits every 3 months (±2 weeks) for the first 24 months and every 6 months (±4 weeks) thereafter, with survival status also captured during the long-term survival follow-up phase, including formal survival checks at 48 and 60 months post-randomisation of the final participant. Participants are followed until death or censoring at last known follow-up, ensuring continuous assessment of this endpoint throughout the study duration.
Secondary outcome [5] 463166 0
Radiographic Progression-Free Survival (PFS)
Timepoint [5] 463166 0
Radiographic progression-free survival (PFS) is assessed from randomisation until radiographic progression or censoring at last follow-up using PSMA-PET/CT imaging. Patients are reviewed every 3 months for the first 24 months and every 6 months thereafter, with imaging performed as clinically indicated (e.g. rising PSA or symptoms), and follow-up continuing for approximately 3 years or until progression occurs.
Secondary outcome [6] 463167 0
Overall Survival (OS)
Timepoint [6] 463167 0
Patients are monitored at regular follow-up visits every 3 months for the first 24 months and every 6 months thereafter, with additional dedicated survival follow-up assessments conducted at 48 and 60 months after randomisation of the final participant. Assessment continues until death or censoring at last known follow-up, ensuring comprehensive capture of survival outcomes over the full study duration.
Secondary outcome [7] 463168 0
The HRQoL endpoint is defined as time to deterioration in quality of life, measured using the Functional Assessment of Cancer Therapy – Prostate (FACT-P) questionnaire.
Timepoint [7] 463168 0
HRQoL is assessed using the FACT-P questionnaire at baseline (screening) and then at each scheduled follow-up visit, which occur every 3 months (±2 weeks) for the first 24 months and every 6 months (±4 weeks) thereafter. This allows for regular, longitudinal evaluation of quality of life from randomisation through the full follow-up period

Eligibility
Key inclusion criteria
Participants must meet all of the following criteria:

Adult males aged 18 years or older
Histologically or cytologically confirmed prostate cancer with metastatic disease (M1) detected on PSMA-PET/CT imaging within 8 weeks prior to randomisation
Presence of 4 to 10 metastatic lesions identified on PSMA-PET/CT
Hormone-sensitive or hormone-naïve disease (i.e. not castration-resistant)
ECOG performance status 0–1
All identified metastatic sites must be considered amenable to safe treatment with stereotactic ablative radiotherapy (SABR)
Estimated life expectancy greater than 24 months
Willing and able to provide written informed consent

Additional eligibility considerations:

Prior treatment to metastatic sites is permitted if the site is controlled or requires SABR as per protocol criteria
Prior androgen deprivation therapy (ADT) is permitted if completed >24 months prior, or if testosterone has recovered to eugonadal levels before enrolment
Minimum age
18 Years
Maximum age
No limit
Sex
Males
Healthy volunteers
No
Key exclusion criteria
Participants will be excluded if they have castration-resistant prostate cancer, more than ten metastatic lesions at baseline, or serious medical conditions that make the safe delivery of stereotactic ablative radiotherapy unsuitable. Exclusion also applies to individuals with brain metastases, leptomeningeal disease, spinal cord compression, or malignant pleural effusion. Patients with tumour histology showing significant sarcomatoid, ductal, spindle cell, or neuroendocrine (small cell) features are not eligible, nor are those with an active malignancy other than prostate cancer, except for adequately treated non-melanoma skin cancer or superficial bladder cancer. Individuals with a prior non-prostate malignancy are excluded unless they have been disease-free for three years following their last treatment. Patients with known radiation sensitivity syndromes or connective tissue disorders that increase the risk from radiotherapy are also excluded.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation will be concealed using a secure, third-party, web-based randomisation system. Randomisation is performed centrally, ensuring that treatment allocation is not known to investigators or site staff prior to participant enrolment and assignment.
Randomisation is conducted in randomly varying block sizes (2 and 4) and incorporates stratification factors, maintaining allocation concealment throughout the enrolment process.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Participants are randomised in a 1:1 ratio using block randomisation with variable block sizes of 2 and 4 (randomly varying), which helps maintain balance between treatment arms.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD,TAS,WA,VIC

Funding & Sponsors
Funding source category [1] 322135 0
Charities/Societies/Foundations
Name [1] 322135 0
Icon Cancer Foundation
Country [1] 322135 0
Australia
Primary sponsor type
Charities/Societies/Foundations
Name
Icon Group
Address
Country
Australia
Secondary sponsor category [1] 325026 0
None
Name [1] 325026 0
Address [1] 325026 0
Country [1] 325026 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 320664 0
Bellberry Human Research Ethics Committee A
Ethics committee address [1] 320664 0
Ethics committee country [1] 320664 0
Australia
Date submitted for ethics approval [1] 320664 0
02/04/2026
Approval date [1] 320664 0
Ethics approval number [1] 320664 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 151218 0
Dr Paul Conway
Address 151218 0
Icon cancer centre Richmond - Epworth Centre, Level 4/32 Erin St, Richmond VIC 3121
Country 151218 0
Australia
Phone 151218 0
+61 3 9936 8277
Fax 151218 0
Email 151218 0
Contact person for public queries
Name 151219 0
Bianca Karle
Address 151219 0
Icon group - Level 1/22 Cordelia St, South Brisbane QLD 4101
Country 151219 0
Australia
Phone 151219 0
+61737374500
Fax 151219 0
Email 151219 0
Contact person for scientific queries
Name 151220 0
Paul Conway
Address 151220 0
Icon cancer centre Richmond - Epworth Centre, Level 4/32 Erin St, Richmond VIC 3121
Country 151220 0
Australia
Phone 151220 0
+61 3 9936 8277
Fax 151220 0
Email 151220 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: data will be aggregated for analysis



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.